Improved low-risk criteria scores for combination therapy of sildenafil and generic bosentan in patients with congenital heart disease with severe pulmonary hypertension: A prospective open label study

OBJECTIVE: We evaluated the efficacy and safety of the bosentan as a sequential add-on therapy with sildenafil in pulmonary arterial hypertension with congenital heart disease (PAH-CHD) patients. MATERIAL AND METHOD: Twenty patients who were receiving sildenafil were given generic bosentan for up to...

Descripción completa

Detalles Bibliográficos
Autores principales: Durongpisitkul, Kritvikrom, Chungsomprasong, Paweena, Vijarnsorn, Chodchanok, Chanthong, Prakul, Kanjanauthai, Supaluck, Soongswang, Jarupim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829601/
https://www.ncbi.nlm.nih.gov/pubmed/33614021
http://dx.doi.org/10.1177/2048004020982213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829601/
https://www.ncbi.nlm.nih.gov/pubmed/33614021
http://dx.doi.org/10.1177/2048004020982213

Ejemplares similares